Canada markets open in 2 hours 29 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2400+0.1800 (+8.74%)
At close: 04:00PM EDT
2.3000 +0.06 (+2.68%)
Pre-Market: 06:47AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.0600
Open1.9900
Bid2.2700 x 3200
Ask2.2800 x 2200
Day's Range1.9700 - 2.2800
52 Week Range1.6700 - 17.6500
Volume7,821,789
Avg. Volume11,009,582
Market Cap483.083M
Beta (5Y Monthly)4.69
PE Ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings DateAug 04, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.38
  • Motley Fool

    Is Ocugen Finally on the Way to Vaccine Revenue?

    Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.

  • Motley Fool

    Where Will Ocugen Be in 1 Year?

    The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.

  • Motley Fool

    Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript

    With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.